AC Immune S.A. | Ownership

Companies that own AC Immune S.A.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Management & Research Co.
3,886,249
5.77%
-183,683
0%
06/30/2018
Fidelity (Canada) Asset Management ULC
2,594,173
3.85%
1,353,986
0.04%
06/30/2018
Duquesne Family Office LLC
2,388,700
3.55%
0
1%
06/30/2018
Temasek Holdings Pte Ltd. (Investment Management)
1,337,500
1.99%
0
0.03%
06/30/2018
PointState Capital LP
1,000,000
1.48%
0
0.11%
06/30/2018
Invus Public Equities Advisors LLC
600,000
0.89%
0
0.19%
06/30/2018
Tekla Capital Management LLC
171,813
0.26%
0
0.05%
06/30/2018
FIAM LLC
156,900
0.23%
60,000
0%
06/30/2018
Geode Capital Management LLC
51,448
0.08%
6,260
0%
06/30/2018
Bruno Walter Finance SA
40,000
0.06%
0
0.36%
02/28/2018

About AC Immune

View Profile
Address
EPFL Innovation Park
Lausanne Basel-Landschaft (Basle Country) 1015
Switzerland
Employees -
Website http://www.acimmune.com
Updated 07/08/2019
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, and Andrea Pfeifer on February 13, 2003 and is headquartered in Lausanne, Switzerland.